Type 1 Diabetes Underdiagnosis Kills in Papua New Guinea

Pacific island countries face severe supply bottlenecks and underdiagnosis for the more than one million people living with type 1 diabetes across the World Health Organization’s Western Pacific Region, the Devpolicy Blog from the Development Policy Centre reported.

Key Clinical Takeaways:

• Type 1 diabetes is an autoimmune condition where the pancreas stops producing insulin, requiring daily management distinct from type 2 diabetes.
• Global prevalence sits at 115.5 per 100,000 people, but drops to 43.1 per 100,000 in the Western Pacific due to heavy underdiagnosis and early mortality from diabetic ketoacidosis.
• Geographic remoteness and high transport costs lead to chronic insulin stockouts and storage challenges across Pacific island nations.

Missed diagnoses drive early deaths because untreated type 1 diabetes quickly poisons the blood with acids when the body cannot use glucose, resulting in diabetic ketoacidosis. According to the Type 1 Diabetes Index cited by the Devpolicy Blog from the Development Policy Centre, an estimated 314 people in Papua New Guinea would still be alive today had they not died early from the condition.

Someone diagnosed at the age of 10 in Papua New Guinea can expect to live to 33 years old. That contrasts sharply with a life expectancy of 69 years for the general population without the condition.

Geographic remoteness and small populations make pharmaceutical distribution commercially unattractive for manufacturers due to high transport costs and few customers. Shipped medicines can take months to arrive, and cargo vessels frequently lack the refrigerated storage that insulin requires to maintain potency.

Keeping insulin cold once it reaches shore remains difficult in rural areas. While insulin is free or subsidised in the public health systems of many Pacific countries, frequent stockouts force patients to purchase available supplies commercially at higher prices.

Automatic insulin pumps guided by continuous glucose monitors improve long-term health outcomes, but high costs keep them out of reach for underserved populations. Insulin pumps cost between 7,000 and 10,000 Australian dollars out of pocket, though Australian families access them through private health insurance or the Insulin Pump Program for lower-income households.

The team that isolated and injected insulin in 1922 sold the patent for one dollar, declaring that the treatment belonged to the world. Pump manufacturers such as Medtronic and Insulet run charitable foundations and access programs aimed at reaching underserved populations, offering potential avenues to expand technology availability through collaboration between governments, pharmaceutical companies, and development partners.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.